Analysts Issue Forecasts for ELDN Q1 Earnings

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) – Analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for Eledon Pharmaceuticals in a research report issued to clients and investors on Wednesday, June 18th. HC Wainwright analyst Y. Chen expects that the company will earn ($0.32) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $9.00 target price on the stock. The consensus estimate for Eledon Pharmaceuticals’ current full-year earnings is ($0.81) per share. HC Wainwright also issued estimates for Eledon Pharmaceuticals’ Q2 2026 earnings at ($0.32) EPS, Q3 2026 earnings at ($0.29) EPS and Q4 2026 earnings at ($0.27) EPS.

Eledon Pharmaceuticals (NASDAQ:ELDN) last announced its quarterly earnings data on Wednesday, May 14th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.28) by $0.20.

Separately, Wall Street Zen cut Eledon Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, June 6th.

Eledon Pharmaceuticals Stock Down 1.1%

Shares of NASDAQ:ELDN opened at $2.78 on Thursday. Eledon Pharmaceuticals has a 52-week low of $2.30 and a 52-week high of $5.54. The stock has a market cap of $166.47 million, a P/E ratio of -1.32 and a beta of -0.17. The business’s 50 day moving average is $3.04 and its 200 day moving average is $3.72.

Institutional Trading of Eledon Pharmaceuticals

Hedge funds have recently bought and sold shares of the stock. Tower Research Capital LLC TRC lifted its holdings in Eledon Pharmaceuticals by 418.5% during the fourth quarter. Tower Research Capital LLC TRC now owns 7,944 shares of the company’s stock worth $33,000 after buying an additional 6,412 shares during the period. CW Advisors LLC purchased a new stake in Eledon Pharmaceuticals during the first quarter worth $34,000. Y Intercept Hong Kong Ltd purchased a new stake in Eledon Pharmaceuticals during the first quarter worth $41,000. Alpine Global Management LLC purchased a new stake in Eledon Pharmaceuticals during the fourth quarter worth $56,000. Finally, ADAR1 Capital Management LLC purchased a new stake in Eledon Pharmaceuticals during the fourth quarter worth $66,000. Hedge funds and other institutional investors own 56.77% of the company’s stock.

About Eledon Pharmaceuticals

Eledon Pharmaceuticals, Inc operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).